Molecular pathways as novel therapeutic targets in systemic sclerosis

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 568-573

  Trojanowska, Maria ^a   Varga, John ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Collagen; Fibroblast; Fibrosis; Systemic sclerosis; Transforming growth factor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABELSON KINASE; ANTIFIBROTIC AGENT; BIOLOGICAL MARKER; COLLAGEN; IMATINIB; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SMAD PROTEIN; TRANSCRIPTION FACTOR FLI 1; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR;

FIBROBLAST; GENE ACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; MEDIATOR RELEASE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TISSUE INJURY;

ANIMALS; FIBROBLASTS; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 34948826895     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282e6f495     Document Type: Review

References (46)

1. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972; 135:1351-1362.
2. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54:880-889.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117:557-567.
4. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26:587-595.
5. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007; 39:42-53.
6. Pannu J, Trojanowska M. Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 2004; 16:739-745.
7. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005; 7:156-162.
8. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001; 44:474-480.
9. Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 2006; 126:1733-1744. This study demonstrates that pharmacological blockade of the ASLK5 TGF-β receptor on normal fibroblasts results in abrogation of TGF-β-induced fibrotic responses such as stimulation of collagen and connective tissue growth factor. Remarkably, treatment of SSc fibroblasts with the ALK5 inhibitor resulted only in an incomplete normalization of abnormally activated genes, and failed to reverse constitutive myofibroblast differentiation of these cells.
10. Pannu J, Gardner H, Shearstone JR, et al. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum 2006; 54:3011-3021.
11. Chen Y, Shi-wen X, Eastwood M, et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006; 54:1309-1316.
12. Gardner H, Shearstone JR, Bandaru R, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54:1961-1973. This multicenter study compared, for the first time, gene profiles of SSc biopsies and cultured fibroblasts obtained from the same patients with those of closely matched healthy individuals. The significance of this study is twofold. First, it demonstrated that SSc biopsies display highly consistent gene profiles that differ significantly from healthy skin and suggested pathological changes in multiple pathways in this disease. Second, it revealed the limitation of studying cultured SSc fibroblasts as a sole model of the disease.
13. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003; 100:12319-12324.
14. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19:2783-2810.
15. Miyazono K, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 2000; 75:115-157.
16. Asano Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113:253-264.
17. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48:1964-1978.
18. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003; 12:817-828.
19. Abe H, Matsubara T, Iehara N, et al. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004; 279:14201-14206.
20. Matsubara T, Abe H, Arai H, et al. Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab Invest 2006; 86:357-368.
21. Takahashi T, Abe H, Arai H, et al. Activation of STAT3/Smad1 is a key signaling pathway for progression to glomerulosclerosis in experimental glomerulonephritis. J Biol Chem 2005; 280:7100-7106.
22. Pannu J, Nakerakanti S, Smith E, et al. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007; 282:10405-10413. This work shows for the first time that Smad1 is required, in parallel with Smad3, for the TGF-β induction of collagen and connective tissue growth factor genes. It also demonstrates that ERK1/2 is involved in regulating the phosphorylation status of Smad1, thus providing a direct link for these two profibrotic pathways.
23. Holmes A, Abraham DJ, Chen Y, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003; 278:41728-41733.
24. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6:827-837.
25. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002; 4:157-164.
26. Tourkina E, Gooz P, Pannu J, et al. Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005; 280:13879-13887.
27. Svegliati S, Cancello R, Sambo P, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005; 280:36474-36482.
28. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive upregulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44:2653-2664.
29. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354:2667-2676. This study demonstrated the presence stimulatory antibodies to the PDGF receptors in serum from patients with limited and diffuse SSc. These pathogenic authoantibodies induced the Ha-Ras-ERK1 and ROS cascade and stimulated collagen gene expression.
30. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114:1308-1316.
31. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311-322. This study demonstrated that imatinib mesylate, an inhibitor of c-Abl and Bcr-c-Abl kinase activity, as well as of PDGF receptor, could block the development of skin fibrosis elicited in normal mice by repeated injections of bleomycin. Whether imatinib was able to attenuate the process in mice that already had evidence of fibrosis was not addressed. In light of the availability of imatinib as a potent antileukemic drug, clinical trials of its efficacy in fibrosis and SSc are to be expected.
32. Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006; 281:21183-21197.
33. Yu J, de Belle I, Liang H, Adamson ED. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol Cell 2004; 15:83-94.
34. Cho SJ, Kang MJ, Homer RJ, et al. Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling. J Biol Chem 2006; 281:8161-8168.
35. Eckes B, Zigrino P, Kessler D, et al. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 2000; 19:325-332.
36. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alpha(v)-beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005; 175:7708-7718.
37. Asano Y, Ihn H, Yamane K, et al. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 2004; 164:1275-1292.
38. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168:499-510.
39. Mimura Y, Ihn H, Jinnin M, et al. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol 2005; 166:1451-1463.
40. Czuwara-Ladykowska J, Shirasaki F, Jackers P, et al. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276:20839-20848.
41. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163:571-581.
42. Nakerakanti SS, Kapanadze B, Yamasaki M, et al. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281:25259-25269.
43. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271-2279.
44. Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004; 50:1305-1318.
45. Cheng S, Afif H, Martel-Pelletier J, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta- induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004; 279:22057-22065.
46. Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 2007; 76:103-112.